Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Capivasertib

FDA-approved product (tablet, oral), marketed as Truqap.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Capivasertib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Capivasertib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Capivasertib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer

    NCT07793578 · start 2026-10-01

    Registered record
    Registry ID
    NCT07793578
    Conditions
    Advanced Urothelial Carcinoma
    Interventions
    capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2030-09-30
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Urothelial Carcinoma
    Interventioncapivasertib
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Fast-Her: Fasting Effects on Breast Cancer Treatment

    NCT07624617 · start 2026-05-18

    Registered record
    Registry ID
    NCT07624617
    Conditions
    Metastatic Breast Cancer
    Interventions
    Normal Eating; Prolonged Fasting
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-05-18
    Completion
    2027-07-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionNormal Eating; Prolonged Fasting
    PhaseNot applicable
    Registry statusRecruiting

  • Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

    NCT07486648 · start 2026-05-15

    Registered record
    Registry ID
    NCT07486648
    Conditions
    Lung Cancer (NSCLC); Lung Cancer (Non-Small Cell); Advanced Non-small-cell Lung Cancer
    Interventions
    Capivasertib in combination with Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-05-15
    Completion
    2028-12-31
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer (NSCLC); Lung Cancer (Non-Small Cell); Advanced Non-small-cell Lung Cancer
    InterventionCapivasertib in combination with Osimertinib
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

    NCT07241065 · start 2026-03-19

    Registered record
    Registry ID
    NCT07241065
    Conditions
    Healthy Participants
    Interventions
    Dextromethorphan; Capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-03-19
    Completion
    2026-07-20
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionDextromethorphan; Capivasertib
    PhasePhase 1
    Registry statusCompleted

  • CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

    NCT07294677 · start 2026-03-17

    Registered record
    Registry ID
    NCT07294677
    Conditions
    Leukemia; Lymphoma
    Interventions
    Capivasertib; Venetoclax; Rituximab; Blinatumomab; Nelarabine; mini-hyperCVD
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-03-17
    Completion
    2032-03
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    InterventionCapivasertib; Venetoclax; Rituximab; Blinatumomab +2 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    NCT07287917 · start 2026-01-26

    Registered record
    Registry ID
    NCT07287917
    Conditions
    Melanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer
    Interventions
    AMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-01-26
    Completion
    2028-12-29
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer
    InterventionAMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

    NCT07343960 · start 2026-01-06

    Registered record
    Registry ID
    NCT07343960
    Conditions
    Moderate Hepatic Impairment
    Interventions
    Capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-01-06
    Completion
    2026-11-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Hepatic Impairment
    InterventionCapivasertib
    PhasePhase 1
    Registry statusRecruiting

  • CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

    NCT06927648 · start 2025-10-15

    Registered record
    Registry ID
    NCT06927648
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-10-15
    Completion
    2029-12-30
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521 · start 2025-08-26

    Registered record
    Registry ID
    NCT06982521
    Conditions
    PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer
    Interventions
    Zovegalisib; Capivasertib; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-08-26
    Completion
    2031-12-31
    Enrolment
    540

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor; Breast Cancer +2 more
    InterventionZovegalisib; Capivasertib; Fulvestrant
    PhasePhase 3
    Registry statusRecruiting

  • Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

    NCT07008963 · start 2025-07-31

    Registered record
    Registry ID
    NCT07008963
    Conditions
    Metastatic Breast Cancer
    Interventions
    non-interventional
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-07-31
    Completion
    2025-11-28
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    Interventionnon-interventional
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Capivasertib on ctDNA in ER Positive Breast Cancer

    NCT06613516 · start 2025-02-01

    Registered record
    Registry ID
    NCT06613516
    Conditions
    Breast Cancer; Oestrogen Receptor Positive Breast Cancer
    Interventions
    Capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-02-01
    Completion
    2025-09-16
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Oestrogen Receptor Positive Breast Cancer
    InterventionCapivasertib
    PhasePhase 2
    Registry statusWithdrawn

  • A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

    NCT06764186 · start 2025-01-07

    Registered record
    Registry ID
    NCT06764186
    Conditions
    Locally Advanced or Metastatic Breast Cancer
    Interventions
    Fulvestrant; Capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2025-01-07
    Completion
    2027-12-31
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced or Metastatic Breast Cancer
    InterventionFulvestrant; Capivasertib
    PhasePhase 3
    Registry statusActive not recruiting

  • Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

    NCT06607757 · start 2024-12-04

    Registered record
    Registry ID
    NCT06607757
    Conditions
    CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
    Interventions
    Capivasertib; Fulvestrant injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12-04
    Completion
    2026-08-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCCCA Assessed by Ki67 Drop Below <2.7% From Baseline
    InterventionCapivasertib; Fulvestrant injection
    PhasePhase 2
    Registry statusRecruiting

  • A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

    NCT05593497 · start 2024-05-31

    Registered record
    Registry ID
    NCT05593497
    Conditions
    High-Risk Prostate Cancer
    Interventions
    Capivasertib; abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-31
    Completion
    2027-08-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-Risk Prostate Cancer
    InterventionCapivasertib; abiraterone acetate
    PhasePhase 2
    Registry statusRecruiting

  • First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    NCT05768139 · start 2023-04-17

    Registered record
    Registry ID
    NCT05768139
    Conditions
    Breast Cancer; Solid Tumors, Adult
    Interventions
    STX-478; Fulvestrant; Ribociclib; Palbociclib; Letrozole; Anastrozole; Exemestane; Tamoxifen; Abemaciclib; Imlunestrant; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-04-17
    Completion
    2030-07
    Enrolment
    880

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Solid Tumors, Adult
    InterventionSTX-478; Fulvestrant; Ribociclib; Palbociclib +7 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting